Terms ending in 2032
Every in-force patent on Genmab A/S's record whose computed term ends in 2032, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 9,322,035 | Recombinant IGG4 Monovalent Antibodies In force · High confidence | Genmab A/S | In force | High confidence | |
| US 9,212,230 | Bispecific Antibodies and Methods for Production Thereof In force · High confidence | Genmab A/S | In force | High confidence | |
| US 11,046,771 | Monoclonal Antibodies Against HER2 In force · High confidence | Genmab A/S | In force | High confidence | |
| US 10,793,640 | Monoclonal Antibodies Against HER2 Epitope In force · High confidence | Genmab A/S | In force | High confidence | |
| US 11,578,141 | Bispecific Antibodies Against HER2 and CD3 In force · High confidence | Genmab A/S | In force | High confidence | |
| US 9,862,769 | Monoclonal Antibodies Against HER2 In force · High confidence | Genmab A/S | In force | High confidence | |
| US 11,512,140 | Monoclonal Antibodies Against C-Met In force · Medium confidence | Genmab A/S | In force | Medium confidence | |
| US 11,091,553 | Monoclonal Antibodies Against HER2 In force · High confidence | Genmab A/S | In force | High confidence | |
| US 9,540,433 | Human Antibodies and Antibody-Drug Conjugates Against CD74 In force · High confidence | Genmab A/S | In force | High confidence | |
| US 11,795,214 | Modulation of Complement-Dependent Cytotoxicity Through Modifications of the C-Terminus of Antibody Heavy Chains In force · High confidence | Genmab A/S | In force | High confidence | |
| 2 more term ends in 2032 · Pro | |||||
10 of 12 patents shown. Soonest term end first, then patent number.
Pro members see all 12.
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.